MFG
BMRN icon

Menard Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Menard Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,658
Closed -$205K – 151
2021
Q3 		$205K Buy
+2,658
New +$210K 0.18% 155
2020
Q3 		– Sell
-1,760
Closed -$217K – 140
2020
Q2 		$217K Buy
+1,760
New +$175K 0.27% 98

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Menard Financial Group's BMRN Position: Q4 2021 in Review

Menard Financial Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 2,658 shares — an estimated $205K sold.

Menard Financial Group first reported a position in BMRN in Q2 2020 and held it in 2 quarters. The position peaked at $217K in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Menard Financial Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Menard Financial Group sold 2,658 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $205K.
  • Menard Financial Group first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Menard Financial Group's BioMarin Pharmaceuticals position peaked at $217K in Q2 2020.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Menard Financial Group's 13F filing for Q4 2021, filed 14 Feb 2022.